Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tagraxofusp - Stemline Therapeutics

Drug Profile

Tagraxofusp - Stemline Therapeutics

Alternative Names: Diphtheria-toxin-interleukin-3-fusion-protein; DT(388)IL3; DT-388-IL-3; DT-IL-3; ELZONRIS; Elzonris; NS-401; SL-401; tagraxofusp-erzs

Latest Information Update: 08 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scott & White Healthcare; Texas A&M University
  • Developer Dana-Farber Cancer Institute; Nippon Shinyaku; Stemline Therapeutics
  • Class Antineoplastics; Bacterial toxins; Immunotoxins; Interleukins; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Peptide elongation factor 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Blastic plasmacytoid dendritic cell neoplasm
  • Phase II Acute myeloid leukaemia; Myeloproliferative disorders
  • Phase I/II Multiple myeloma; Myelodysplastic syndromes
  • No development reported Hairy cell leukaemia; Systemic scleroderma

Most Recent Events

  • 01 May 2024 Phase-II clinical trials in Acute myeloid leukaemia (Combination therapy) in USA (IV) (NCT05442216)
  • 13 Mar 2024 Stemline Therapeutics and Jonsson Comprehensive Cancer Center withdraws a phase-I trial in Acute myeloid leukaemia (Monotherapy, Combination therapy) prior to enrolment in the US (IV) (NCT05720988)
  • 09 Dec 2023 Efficacy and adverse events data from phase I/II trial in Myelodysplastic syndromes presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top